# US 2026/0060933 A1 · Lithium salt extended-release formulations; methods of making; and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060933 A1
- Document ID: US20260060933A1
- Status: Published application
- Kind: A1
- Application number: 19/379,854
- Filed: 2025-11-05
- Published: 2026-03-05
- Earliest claimed: 2023-06-23
- Assignees: Almatica Pharma LLC
- Applicants: Almatica Pharma LLC
- Inventors: Ripal Gaudana; Raghav Gupta; Rama Yarasani
- Web page: https://patentgrep.com/patent/US20260060933A1

## CPC

- A61K 9/0065: {Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2086: {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/10: Carbonates; Bicarbonates
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are high dose gastric retentive, extended-release lithium salt dosage forms suitable for once a day administration.

## Claims

### Claim 1

An extended-release, bilayer oral tablet, comprising:
a.) a first layer comprising an extended-release polymer matrix portion comprising
about 70 to about 80 wt % lithium carbonate,
about 10 to about 20 wt % of a hydroxypropyl methyl cellulose, polyvinylpyrrolidone,
microcrystalline cellulose, and
a glidant, a lubricant, or a combination thereof,
wherein the weight percents of lithium carbonate and hydroxypropyl methyl cellulose are based on the total weight of the extended-release polymer matrix portion;
b.) a second layer comprising a gastroretentive portion comprising
about 75 to about 85 wt % of a swellable polymer based on the total weight of the gastroretentive portion, wherein the swellable polymer is a high molecular weight polyethylene oxide,
a hydroxypropyl methyl cellulose, and
a lubricant, a colorant, or a combination thereof; and
c.) a film coating;
wherein the tablet contains about 600 mg lithium carbonate per tablet and a weight ratio of the extended-release polymer matrix portion to the gastroretentive portion is about 2.5:1 to about 1.5:1; or
wherein the tablet contains about 900 mg lithium carbonate per tablet and a weight ratio of the extended-release polymer matrix portion to the gastroretentive portion is about 3.5:1 to about 2.5:1.

### Claim 2 (depends on 1)

The tablet of claim 1, wherein the tablet contains about 600 mg lithium carbonate.

### Claim 3 (depends on 1)

The tablet of claim 1, wherein the tablet contains about 900 mg lithium carbonate.

### Claim 4 (depends on 1)

A method of treating a subject in need thereof, comprising:
administering the tablet of claim 1 once daily to the subject to treat depression or mania.

### Claim 5 (depends on 1)

A method of treating a subject in need thereof, comprising:
administering the tablet of claim 1 once daily with food to the subject to treat depression or mania.
